Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,823 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10205
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
· N Engl J Med · 2019 · PMID 31157963 · validated civic_curation pubmed
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
· N Engl J Med · 2021 · PMID 34081848 · validated civic_curation pubmed
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2016 · PMID 26874901 · validated civic_curation pubmed
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
· N Engl J Med · 2005 · PMID 16236737 · validated civic_curation pubmed
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
· Lancet · 2010 · PMID 20728210 · validated civic_curation pubmed
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
· N Engl J Med · 2025 · PMID 39908431 · validated civic_curation pubmed
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
· Lancet Oncol · 2012 · PMID 22452895 · validated civic_curation

Showing 1–25 of 384 publications

← Previous
1
2
…
16
Next →

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.

· Horm Metab Res · 2014 · PMID 24570209 · validated civic_curation pubmed

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

· Clin Endocrinol (Oxf) · 2014 · PMID 24354346 · validated civic_curation pubmed

Integrated molecular analysis of clear-cell renal cell carcinoma.

· Nat Genet · 2013 · PMID 23797736 · validated civic_curation pubmed

Comprehensive molecular characterization of clear cell renal cell carcinoma.

· Nature · 2013 · PMID 23792563 · validated cbioportal_study pubmed

Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.

· Nat Genet · 2014 · PMID 24658004 · validated civic_curation pubmed

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

· N Engl J Med · 2001 · PMID 11248153 · validated civic_curation pubmed

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

· J Clin Oncol · 2005 · PMID 15911866 · validated civic_curation pubmed

DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

· Mod Pathol · 2015 · PMID 25698061 · validated civic_curation pubmed

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

· N Engl J Med · 2015 · PMID 25693012 · validated civic_curation pubmed

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28958504 · validated civic_curation pubmed

Cyclin E in human cancers.

· FASEB J · 1999 · PMID 10224221 · validated civic_curation pubmed

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

· Science · 2014 · PMID 24578576 · validated civic_curation pubmed

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.

· Int J Cancer · 2008 · PMID 18464292 · validated civic_curation pubmed

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

· J Clin Invest · 2005 · PMID 15630448 · validated civic_curation pubmed

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

· Br J Cancer · 2007 · PMID 17700571 · validated civic_curation pubmed

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

· Eur J Cancer · 2014 · PMID 24915778 · validated civic_curation pubmed

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

· Gastroenterology · 2015 · PMID 25557953 · validated civic_curation pubmed